Lionel Ginsberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lionel Ginsberg has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
D. Kidd
Department of Neurology, Royal Free Hospital, London, UK
1 shared publication- Gabor E. Linthorst
Department of Internal Medicine, Division Endocrinology and Metabolism, Academic Medical Centre, Room F5-166, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
1 shared publication - Helen J. Lachmann
10National Amyloidosis Center, University College London, Royal Free Hospital, London, United Kingdom
1 shared publication M. Maviki
Department of Radiology, Royal Free Hospital, London, UK
1 shared publicationP. N. Hawkins
National Amyloidosis Centre, UCL, London, UK
1 shared publicationRachel Brown
Royal Free Hospital
1 shared publication
Latest Publications
- Open Access
- 29 November 2018
- Published by Springer Nature in Journal of Neurology
- Vol. 266 (1) , 268-277
POEMS syndrome: clinical update
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) is a rare paraneoplastic syndrome, caused by a plasma cell proliferative disorder, which is most commonly lambda restricted. The neurological hallmark, which forms one of the mandatory criteria for diagnosis, is a subacute onset demyelinating neuropathy, which can be rapidly disabling and painful. A number of multi-system features are also characteristic of this disorder, and certainly not restricted to those included in its acronym, which though limited, remains a useful and memorable name, helping distinguish POEMS syndrome from other paraproteinaemic neuropathies. The discovery of vascular endothelial growth factor (VEGF) in association with POEMS syndrome has been extremely useful in aiding clinical diagnosis, and monitoring response to treatment, as well as helping understand the underlying mechanism of disease. Interestingly, however, treatment targeting VEGF has been disappointing, suggesting other disease mechanisms or inflammatory processes are also important. Current understanding of the pathogenesis of POEMS syndrome is outlined in detail in the accompanying article by Cerri et al. Here, we review the clinical features of POEMS syndrome, differential diagnosis and available treatment options, based on current literature.
- 29 November 2018
- Published by Springer Nature in Journal of Neurology
- Vol. 266 (1) , 268-277
Open AccessPOEMS syndrome: clinical update
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) is a rare paraneoplastic syndrome, caused by a plasma cell proliferative disorder, which is most commonly lambda restricted. The neurological hallmark, which forms one of the mandatory criteria for diagnosis, is a subacute onset demyelinating neuropathy, which can be rapidly disabling and painful. A number of multi-system features are also characteristic of this disorder, and certainly not restricted to those included in its acronym, which though limited, remains a useful and memorable name, helping distinguish POEMS syndrome from other paraproteinaemic neuropathies. The discovery of vascular endothelial growth factor (VEGF) in association with POEMS syndrome has been extremely useful in aiding clinical diagnosis, and monitoring response to treatment, as well as helping understand the underlying mechanism of disease. Interestingly, however, treatment targeting VEGF has been disappointing, suggesting other disease mechanisms or inflammatory processes are also important. Current understanding of the pathogenesis of POEMS syndrome is outlined in detail in the accompanying article by Cerri et al. Here, we review the clinical features of POEMS syndrome, differential diagnosis and available treatment options, based on current literature.
- 13 June 2017
- Published by Springer Nature
- p. 105-116
Monogenic Disorder: Fabry Disease
- Open Access
- 2 March 2016
- Published by Wiley in European Journal of Neurology
- Vol. 23 (7) , 1145-1151
Neurology of the cryopyrin‐associated periodic fever syndrome
Background and purpose: The cryopyrin‐associated periodic fever syndrome (CAPS) is an autosomal dominant autoinflammatory disorder caused by mutations in the NLRP3 gene and is typified by recurrent episodes of systemic inflammation resulting in fever, urticarial rash and arthralgia. In addition to these systemic aspects, CAPS has multiple neurological manifestations. The largest case series to date is presented focusing on the neurological features of this disorder.Methods: The case histories of a cohort of 38 UK patients with genetically proven CAPS who were treated with interleukin 1β (IL‐1β) inhibition as part of a national treatment programme and underwent detailed neurological assessment were reviewed.Results: Across the entire disease course neurological manifestations were present in 95% of patients; 84% had some form of headache; 66% sensorineural hearing loss; 60% myalgia; 34% papilloedema and 26% optic atrophy. Patients with the T348M mutation tended to have a more severe neurological phenotype with an earlier age of onset. Four patients had cerebrospinal fluid examination, three of whom had evidence of aseptic meningitis. There was a marked response to IL‐1β inhibition, which has revolutionized management of these patients (29/32 patients with headache responding).Conclusion: Neurological symptoms are extremely common in CAPS and these results highlight the importance of increasing awareness amongst neurologists, particularly as highly effective therapies are available.
- 2 March 2016
- Published by Wiley in European Journal of Neurology
- Vol. 23 (7) , 1145-1151
Open AccessNeurology of the cryopyrin‐associated periodic fever syndrome
Background and purpose: The cryopyrin‐associated periodic fever syndrome (CAPS) is an autosomal dominant autoinflammatory disorder caused by mutations in the NLRP3 gene and is typified by recurrent episodes of systemic inflammation resulting in fever, urticarial rash and arthralgia. In addition to these systemic aspects, CAPS has multiple neurological manifestations. The largest case series to date is presented focusing on the neurological features of this disorder.Methods: The case histories of a cohort of 38 UK patients with genetically proven CAPS who were treated with interleukin 1β (IL‐1β) inhibition as part of a national treatment programme and underwent detailed neurological assessment were reviewed.Results: Across the entire disease course neurological manifestations were present in 95% of patients; 84% had some form of headache; 66% sensorineural hearing loss; 60% myalgia; 34% papilloedema and 26% optic atrophy. Patients with the T348M mutation tended to have a more severe neurological phenotype with an earlier age of onset. Four patients had cerebrospinal fluid examination, three of whom had evidence of aseptic meningitis. There was a marked response to IL‐1β inhibition, which has revolutionized management of these patients (29/32 patients with headache responding).Conclusion: Neurological symptoms are extremely common in CAPS and these results highlight the importance of increasing awareness amongst neurologists, particularly as highly effective therapies are available.
- 1 November 2012
- Published by Wiley in European Journal of Neurology
- Vol. 19 (11) , 1383-1384
Prevalence of Fabry disease in TIA/stroke cohorts. What defines Fabry disease?
- 1 November 2012
- Published by Wiley in European Journal of Neurology
- Vol. 19 (11) , 1383-1384
Prevalence of Fabry disease in TIA/stroke cohorts. What defines Fabry disease?
- 10 July 2011
- Published by BMJ in Practical Neurology
- Vol. 11 (4) , 259-267
Disorders of the spinal cord and roots
- 10 July 2011
- Published by BMJ in Practical Neurology
- Vol. 11 (4) , 259-267
Disorders of the spinal cord and roots